Reading Time: 1 minute
Last year, Medios AG (i.) acquired the fast-growing Dutch company Ceban Pharmaceuticals B.V. In addition to expanding into the Netherlands, Belgium, and Spain, the company simultaneously incorporated a highly profitable niche specialist with an EBITDA margin of 18% at that time. For comparison, Medios' margin before the acquisition was around 3.4%, based on the fact that drug price regulations in Germany impose price limits. Therefore, the acquisition is proving to be beneficial! Medios was able to announce a record quarter in November with strong...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
